InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Announcements

Current share price for NUZ : $0.078 0.001 (1.27%)+

ASX company news and announcements for Neurizon Therapeutics Limited (NUZ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurizon Therapeutics Limited (NUZ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurizon Therapeutics Limited (NUZ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurizon Therapeutics Limited (NUZ)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$62 HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule 12 Jun 2026 9:07AM $0.060 $0.078 risen by 30%
$62 Application for quotation of securities - NUZ 2 Jun 2026 5:32PM $0.063 $0.078 risen by 23.81%
$62 Webinar presentation - Regimen I expands to 240 participants 28 May 2026 3:24PM $0.063 $0.078 risen by 23.81%
$62 HEALEY ALS Trial Regimen I Expands to 240 Participants 27 May 2026 9:20AM $0.062 $0.078 risen by 25.81%
$62 Ethics Approval Received for NUZ-001 Oral Liquid P1 Study 13 May 2026 9:19AM $0.074 $0.078 risen by 5.41%
$62 Final Director's Interest Notice 12 May 2026 4:27PM $0.074 $0.078 risen by 5.41%
$62 Initial Director's Interest Notice 12 May 2026 4:22PM $0.074 $0.078 risen by 5.41%
$62 Australian Microcap Investment Conference Presentation 11 May 2026 1:20PM $0.075 $0.078 risen by 4%
$62 Neurizon Strengthens Board for the Next Growth Phase 8 May 2026 9:06AM $0.075 $0.078 risen by 4%
$62 Change of Director's Interest Notices 4 May 2026 12:15PM $0.081 $0.078 fallen by 3.70%
$62 Neurizon investor briefing presentation 30 Apr 2026 4:17PM $0.082 $0.078 fallen by 4.88%
$62 Application for quotation of securities - NUZ 30 Apr 2026 4:09PM $0.082 $0.078 fallen by 4.88%
$62 Appendix 4C & Quarterly Update 30 Apr 2026 9:38AM $0.085 $0.078 fallen by 8.24%
$62 Section 708A Cleansing Statement 21 Apr 2026 9:40AM $0.087 $0.078 fallen by 10.34%
$62 Application for quotation of securities - NUZ 21 Apr 2026 9:33AM $0.087 $0.078 fallen by 10.34%
$62 Neurizon Investor Briefings Invitation 16 Apr 2026 2:30PM $0.086 $0.078 fallen by 9.30%
$62 Placement of Entitlement Offer Shortfall 16 Apr 2026 9:28AM $0.089 $0.078 fallen by 12.36%
$62 Investor Presentation - April 2026 10 Apr 2026 9:58AM $0.081 $0.078 fallen by 3.70%
$62 Section 708A Cleansing Statement 1 Apr 2026 4:39PM $0.078 $0.078 fallen by 0%
$62 Application for quotation of securities - NUZ 1 Apr 2026 4:25PM $0.078 $0.078 fallen by 0%
$62 NUZ-001 Data Shows Multi-Pathway Protein Clearance 1 Apr 2026 9:46AM $0.075 $0.078 risen by 4%
$62 Change of Director's Interest Notices x4 26 Mar 2026 8:18AM $0.080 $0.078 fallen by 2.50%
$62 Notification of Expiry of NUZOA Listed Options 20 Mar 2026 9:48AM $0.084 $0.078 fallen by 7.14%
$62 Neurizon presents at HEALEY ALS Platform Trial Webinar 20 Mar 2026 8:40AM $0.084 $0.078 fallen by 7.14%
$62 Section 708A Cleansing Statement 19 Mar 2026 11:37AM $0.086 $0.078 fallen by 9.30%

26 - 50 of 184 results

Page 2 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.